Andere talen Dermata Therapeutics, Inc.

Aandelen

DRMA

US2498453065

Beurs gesloten - Nasdaq Andere beurzen 22:30:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,3427 ^USD	+0,76%		+6,73%	-43,82%

21/03	Dermata Therapeutics, Inc. Rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
05/01	Wall Street zal lager openen na veel sterkere maandelijkse banencijfers dan verwacht	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Dermata Therapeutics : Provides Corporate Update and Reports Full Year 2023 Financial Results - Form 8-K	21/03
Dermata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Dermata to Present at the Emerging Growth Conference on February 7, 2024	02/02
Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected	05/01
Investors Await Jobs Data as US Futures Trend Lower in Friday's Premarket	05/01
Top Premarket Gainers	05/01
North American Morning Briefing : Bond Yields Rise Again as Jobs Data Loom	05/01
Dermata Therapeutics, Inc. Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne	20/12
Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols	17/11
Sector Update: Health Care Stocks Slightly Advancing Late Afternoon	16/11
Dermata Therapeutics to Begin Enrolling Patients in Acne Drug Study; To Raise $2.3 Million	16/11
Dermata Therapeutics, Inc. to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 Based on Agreement with FDA on the Phase 3 Protocols	16/11
Dermata Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Dermata Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10-08-23
Dermata Therapeutics, Inc. Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-To-Severe Acne	27-06-23
Dermata Therapeutics, Inc. Announces Positive Results from its DMT310 Phase 2b Study of Its Once-Weekly Topical Treatment in Patients with Moderate-To-Severe Acne Vivis	08-06-23
Dermata Therapeutics Completes $1.8 Million Share Offering	26-05-23
DERMATA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	24-05-23
Certain Warrants of Dermata Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-MAY-2023.	16-05-23
Certain Common Stock of Dermata Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-MAY-2023.	16-05-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Dermata Therapeutics, Inc.

Aandelen

DRMA

US2498453065

Andere talen

Filters